The CRO is adding two new offices in the US to support what has been significant growth over the past several years from pharma and biotech customers working in rare diseases and immune-oncology.
CTI expects to create up to 50 new jobs over the next several years in response to significant growth in the pharma and biotech industry, specifically in cell and gene therapies, says CEO.